Background. Infant botulism (IB), first identified in California in 1976, results from Clostridium botulinum spores that germinate, multiply, and produce botulinum neurotoxin (BoNT) in the immature intestine. From 1976 to 2010 we created an archive of 1090 BoNT-producing isolates consisting of 1012 IB patient (10 outpatient, 985 hospitalized, 17 sudden death), 25 food, 18 dust/soils, and 35 other strains.
Infant botulism (IB) results when swallowed spores of Clostridium botulinum (or rarely, neurotoxigenic C. butyricum or C. baratii) germinate, multiply, and produce botulinum neurotoxin (BoNT) in the large intestine. BoNT, the most poisonous substance known, causes constipation, bulbar palsies, and flaccid paralysis in infants by blocking acetylcholine release at the neuromuscular junction [1] . Approximately 20-50 IB cases occur annually in California, more than in any other state. Since initial identification of IB in California in 1976 [2] [3] [4] , the California Department of Public Health Infant Botulism Treatment and Prevention Program has archived patient epidemiological information and C. botulinum strains isolated from patients' feces and their home environments.
Seven botulinum toxin types (A-G) are currently known (an eighth was recently recognized [5, 6] ); bont gene sequencing has identified toxin subtypes or variants [7] [8] [9] [10] (eg, A1, A2). Although most isolates produce a single toxin type, dual-toxin-producing strains (Ab, Af, Ba, Bf, Bh) [5, [11] [12] [13] [14] and type A strains with an unexpressed bont/B gene, denoted A(B), exist [15] [16] [17] . Neurotoxigenic C. butyricum produces BoNT/E, while neurotoxigenic C. baratii produces BoNT/F [18, 19] .
Because the BoNT gene (bont) cluster is associated with mobile genetic elements, the BoNT-producing clostridia exhibit substantial genomic diversity, identifiable by various molecular techniques (reviewed in [10] ). We utilized amplified fragment-length polymorphism (AFLP) analysis for this study because of its robustness and suitability for examining large collections of C. botulinum isolates [7, 20, 21] , together with real-time polymerase chain reaction (RT-PCR) to identify bont subtypes, and combined the molecular results with epidemiologic and clinical information. This combination provided novel and unexpected insights into both the bacterium and the occurrence of IB in California and other parts of North America in the past 35 years.
METHODS

Case Definition, Case Identification, and Collection of Epidemiologic Data
An IB case was defined as an infant with symptoms consistent with the known paralyzing action of BoNT, including sudden death, in which BoNT or C. botulinum was identified in intestinal contents or feces. Cases outside of California were identified through distribution of Human Botulism Immune Globulin Intravenous (BIG-IV; BabyBIG [1] ) and had C. botulinum freshly isolated from a second fecal specimen or were identified through the Centers for Disease Control and Prevention (CDC) national surveillance reports (http://www.cdc.gov/nationalsurveillance/ botulism-surveillance.html). Cases were assigned to the state and county in which the infant lived for the 2 weeks immediately before onset (defined as the date on which the parent first contacted a medical provider about the symptoms of the illness). The incidence calculations included all US IB cases from 1976 to 2010 and live-births in California by county and nationwide by state, available from the California Department of Public Health (CDPH) at http://www.cdph.ca.gov/data/statistics/Pages/ StatewideBirthStatisticalDataTables.aspx (accessed November 21, 2011) and from the National Center for Health Statistics, Hyattsville, MD, at http://www.cdc.gov/nchs/births.htm (accessed December 8, 2011), respectively. Epidemiological data for all California and BIG-IV-treated patients elsewhere were obtained by home visit and/or telephone interview.
Culture and DNA Isolation
Clostridium botulinum was originally isolated from patient and environmental specimens using standard methods [22] , frozen at −70°C, and then freshly cultured to create cell pellets for DNA isolation (see online Supplementary Data) that followed the protocol for DNA extraction from Gram-positive bacteria using the Qiagen DNeasy Blood and Tissue Kit.
AFLP Analysis
For AFLP analysis, DNA preparations were digested with 2 restriction enzymes selected for A/T-rich genomes, linkers were ligated to the resulting fragments, and a series of PCR amplifications were performed as previously described [7] . Forty DNA fragment sizes were used to create a genetic fingerprint representing each isolate [23] . Clustering analysis of the fragment sizes for the 1091 isolates created a dendrogram with 154 clades. (The nontoxigenic C. sporogenes ATCC 11437 isolate was part of the collection.) Differences of >0.20 genetic distance units, the error inherent to the method, differentiated the clades from each other. (See online Supplementary Data for details.)
Toxin Gene Characterization by RT-PCR
Six hundred thirty-five type A and type B isolates, 58% of the collection, were characterized by RT-PCR to determine the subtype and presence of an unexpressed ("silent") bont/B gene (see online Supplementary Data for primers, probes, and conditions used).
Spatial Analysis
Latitude and longitude coordinates were assigned to the patient's residence address at onset of illness, with ZIP code or city centroid coordinates assigned for nonmatching or missing addresses. For clades with ≥10 isolates, SaTScan (http://www. satscan.org) with a case-control model was used to search for geographic or geographic-temporal clusters within that clade by comparing its IB patient isolates to those of all other California IB patients [24] . Environmental, food, and sudden-death case isolates were excluded from this analysis. Possible geographic-temporal clusters were sought in circular geographic areas of radius ≤125 km and maximum time windows of ≤5 years (see online Supplementary Data for details).
RESULTS
Infant Botulism Occurrence in California and Elsewhere
From 1976 to 2010, 2803 IB cases were reported in the United States; 1093 (39%) occurred in California. Table 1 lists the origins of the 1091 isolates studied. These 1091 isolates included 1012 IB patient isolates: 948 California, 55 other US states, and 9 other countries. These 1012 IB patients included the entire clinical spectrum of IB (ie, 10 outpatient, 985 hospitalized, and 17 sudden-death cases). An additional 79 patient-associated environmental isolates and reference strains were also analyzed. By the mouse neutralization assay, the 1090 neurotoxigenic isolates consisted of 609 (56%) BoNT/A; 345 (32%) BoNT/B; 22 (2%) bivalent BoNT/Af, /Ba, or /Bf; 11 (1%) BoNT/E; 9 (1%) BoNT/F; and 8 (1%) BoNT/C, /D or /G. Eighty-six (8%) strains were A(B) ( Table 1 ).
The distribution of IB cases in California reflected the underlying population, with IB cases generally occurring in or near large population centers in the Los Angeles basin, San Francisco Bay area, and metropolitan San Diego ( Figure 1A -D). However, cases also occurred in less populated rural areas. More than half of California IB cases were caused by BoNT/A strains and approximately one-third by BoNT/B strains. In comparison, bivalent and C. baratii BoNT/F strains were rare. IB incidence from 1976 to 2010 was 6.2/100 000 live-births, almost 3-fold higher than the nationwide incidence of 2.1/100 000 live-births in the same interval. The annual ratio of BoNT/A to BoNT/B cases in California over the 35-year study was 1.7 (range, 0.7-8.5).
AFLP Analysis and bont RT-PCR Characterization
The AFLP dendrogram differentiated the 1091 clostridial isolates into 154 clades, 64 with multiple isolates and 90 with only a single isolate (Figure 2 ; Supplementary Data Appendix I). A striking feature of the dendrogram was its 2 largest clades, 1 containing 418 BoNT/A isolates (n = 387 California IB patients, Figure 1B ) and the other containing 145 BoNT/B isolates (n = 141 California IB patients, Figure 1D ). Hence, these 2 clades contained more than half (563; 52%) of all the isolates in the collection and represented the 2 predominant genotypes of C. botulinum that have caused IB in California for the past 35 years. The other 528 isolates of the collection located to the 152 other clades within the dendrogram.
The bont gene RT-PCR characterization identified subtypes/ variants bont/A1, /A2, /A4, and bont/B1, /B2, /B3, /B4, /B5, and silent B ( Figure 2 ). The Loch Maree BoNT/A3 strain, the only BoNT/A3 isolate in the collection, was included for reference purposes [25, 26] . The 86 A(B) isolates containing the unexpressed bont/(B) gene located to 14 clades; 67 isolates were from California IB patients ( Figure 3A ). Also, a large number of bivalent BoNT/Ba (n = 17), and /Bf (n = 3) and C. baratii type F (n = 2) isolates were obtained from infant botulism cases that occurred in different years and geographic locations in California ( Figure 3C ).
Isolates From Outpatient and Sudden-Death Cases
The clinical spectrum of IB includes outpatient, hospitalized, and fulminant (ie, sudden-death) cases [27, 28] . Ten IB outpatient isolates located to 5 clades: 4 to the largest BoNT/A clade, 
Clades Associated With Honey Consumption
The AFLP analysis produced 2 clades that contained isolates both from honeys and from IB patients fed those honeys before onset of illness. The first clade contained 5 BoNT/A2 isolates from 4 patients (1982, 1995, 1997, 2001 ) and from 1 commercial honey consumed by the 1982 patient. The honeys fed to the other 3 patients were not available for testing. The second clade associated with honey consumption contained 18 patient and 8 honey type B isolates from 1983 to 1988 ( Table 2 ). All 26 isolates were subtyped and determined to be bont/B5. Fourteen (78%) of the 18 patients had been fed honey in the month before onset of illness, and 7 of the 8 honey isolates in this clade were from honeys consumed by 6 of the patients. One patient without a history of honey consumption lived in the honey-producing area.
Clades Associated With Dust and Soils Collected at Patients' Homes
Clostridium botulinum was isolated from 14 environmental samples from the homes of 8 IB patients (Table 1 , footnote b), of which 11 located to the same clade as the patient's isolate. The co-location of patient and environmental isolate(s) in the same clade included: 1 vacuum cleaner dust and 2 soil isolates from the home of 2 sibling type A patients in an Alameda County city; 1 vacuum cleaner dust and 2 soil isolates from Figure 1B) . Two other closely related BoNT/A clades ( Table 2, Figure 3B ).
Bivalent (Ba, Bf ) Clades
The molecular analysis identified 17 bivalent B5a4 isolates that located to 5 clades and 4 B5f isolates, 3 from California and 1 from Texas, that located to 3 clades. The largest of the bivalent clades ( Table 2 , #13) notably contained several B5 and B5a4 isolates and 1 B5f isolate ( Figure 3D) . A single unique strain that contained a bont/A5 gene and a partial bont/B gene [the bont/A5(B3′) gene arrangement [9] ] that was isolated from a San Diego County IB patient located to a singleton clade. Figure 4A ) had a geographic-temporal cluster of 7 patients from 2005 to 2008 centered northeast of Sacramento (radius approximately 101 km; P = .003). The second clade, BoNT/B with 10 IB patient and 1 soil isolate (Table 2, #9; Figure 4B ), had a geographical cluster of 9 patient isolates that centered east of San Francisco Bay (radius of approximately 69 km; P = .002). The third clade, BoNT/B with 30 California IB patient isolates, contained a geographic-temporal cluster from 1992 to 1994 in southern California with 18 patient isolates centered in the San Fernando Valley (Los Angeles County) (radius approximately 97 km; P < .001) (Table 2, #10; Figure 4C ). The fourth clade of 12 BoNT/B California patients that also clustered in southern California both temporally (1980) (1981) (1982) (1983) and geographically was centered near Pasadena (radius approximately 30 km; P = .015) ( Figure 4D ), contained a 2008-2009 geographictemporal cluster of 6 patient isolates centered in the Santa Clarita Valley (Los Angeles County) (radius approximately 68 km; P < .001). Nine of 10 IB patients in this clade became ill in 2008-2009; in 1986, the tenth patient became ill 2 weeks after traveling through the Los Angeles basin (the center of the cluster).
Mid-Atlantic US Type B Clades
DISCUSSION
The Infant Botulism Treatment and Prevention Program (IBTPP) collection of neurotoxigenic clostridial strains provided a unique opportunity to combine molecular and epidemiological information to better understand IB in California. Significant novel findings of this endeavor included: (1) the identification of 2 large clades that contained endemic strains that caused more than half of the BoNT/A and more than one-third of the BoNT/B IB cases in California in the 35-year study period; (2) the co-location of patient isolates from all 3 segments of the IB clinical spectrum (outpatient, hospitalized, sudden death) to the same BoNT/A or BoNT/B clade; (3) the identification of C. botulinum A(B) isolates in IB patients from California and 11 other US states that would not have been identified by the mouse neutralization assay; (4) the identification of rare strains isolated from 25 IB and 2 adult botulism cases that include BoNT/B5a4 (n = 17), BoNT/Bf (n = 4), and C. baratii BoNT/F (n = 6) isolates; (5) the recognition of clades whose isolates share a common-source origin (eg, honey); (6) the identification of clades whose isolates are restricted geographically to limited areas of California; and (7) the co-location to the same clade of C. botulinum patient and associated dust, soil, and honey isolates that could cause IB when swallowed by susceptible infants. The extensive branching of the dendrogram displays and emphasizes the different genetic backgrounds of C. botulinum strains that express the same toxin types.
Clostridium botulinum type A(B) isolates have been reported from Alaska, Arizona, Colorado, Georgia, Illinois, Louisiana, Nebraska, New Mexico, Pennsylvania, Puerto Rico, Wisconsin, and West Virginia [29, [33] [34] [35] . In this study, A(B) isolates were newly identified in IB patients from Arkansas, California, Nevada, Oklahoma, Texas, Washington, and Wyoming, further suggesting that A(B) strains are widespread throughout the United States. The molecular analysis and mouse neutralization assay also identified 17 bivalent BoNT/B5a4 and 3 BoNT/Bf isolates that caused IB in California. Recognition of BoNT/B5a4 strains outside of California that cause IB has occurred infrequently; only the 1976 Texas [36] [37] [38] and 1999 Texas and 2006 Nevada patients reported in the CDC annual national botulism surveillance summaries were previously known.
The AFLP analysis also identified clades that contained isolates associated with honey exposure or that contained geographictemporal clustering. The 4 patients in the only bont/A2 clade were fed honey; the clade also contained a bont/A2 isolate from a honey consumed by 1 of the patients. The BoNT/A2 subtype had previously been isolated only from Argentinian soils and from IB patients in Argentina [39] , Italy [33] , and Japan who were fed honey [40] , as well as from a Brazilian honey [40] and from honey [41] fed to a New Jersey patient that may have contained blended imported Argentinian honey. Because honey may harbor C. botulinum spores, all major public health, pediatric, and honey-producing institutions have recommended that honey not be fed to infants [42] .
Three clusters within California BoNT/B clades occurred in limited time spans: 1 in 1992-1994 ( Figure 4C ), 1 in 2008-2009 ( Figure 4D ), and 1 in 1983-1985 (not shown). The latter occurred in a clade of monovalent BoNT/B5 isolates associated with honey exposure; interestingly, no monovalent BoNT/B5producing isolates have been identified in California since 1988. No common-source exposures to a food or environmental source were identified for the temporal clusters in the 2 other BoNT/B clades. Possible sources of exposure to C. botulinum spores include nonsterile infant foods (eg, powdered infant formulas, dry cereals, herbal teas [43] [44] [45] ), and anthropomorphic activities or weather phenomena that disrupt surface soil [46, 47] .
Geographical localization of isolates in some clades (Figures 1, 3 , and 4) suggests that local soil and/or climatic conditions may contribute to multiplication and subsequent dissemination of C. botulinum spores. Notably, isolates from several patients and their home environments (dust/soil, honey) located to the same clade. Soil surveys in Argentina [48] and the United States [49] have reported differing prevalences and BoNT types in different geographic regions. In the United States, BoNT/A strains predominate in soils west of the Mississippi River, while BoNT/B strains predominate in soils east of the Mississippi River; this regionalization matches the nationwide distribution of IB patient toxin types [22] . Our geographictemporal analyses found that IB isolates from certain clades concentrated in specific geographical areas; for example, a BoNT/A clade northeast of Sacramento ( Figure 4A ), a BoNT/B clade in the San Francisco Bay area ( Figure 4B) , and a BoNT/B clade in the Santa Clarita Valley ( Figure 4D ). Two clades of BoNT/B isolates from patients who resided primarily in the Mid-Atlantic United States or had recently traveled there were also identified. These examples suggest that IB may be acquired from the local environment or while traveling in endemic areas.
In conclusion, the molecular analyses provided new and useful information for elucidating epidemiological relationships and for differentiating C. botulinum isolates. The study resulted in an AFLP dendrogram of 1091 isolates that displays the genetic and epidemiological complexity of neurotoxigenic clostridia (Figure 2 and Supplementary Data Appendix I). Importantly, the geographical clustering of isolates was identified by use of patient epidemiological information. The combination of molecular methods and epidemiological data created an effective tool that yielded novel insights into the genetic diversity of C. botulinum and the clinical spectrum, occurrence, and distribution of IB in California.
